Titre :

In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: proof of concept study in vivo

Auteur(s) :

Batool, Fareeha [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Agossa, Kevimy [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Advanced Drug Delivery Systems (ADDS) - U1008
Lizambard, Martin [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Petit, Catherine [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Bugueno, Isaac Maximiliano [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Delcourt Debruyne, Elisabeth [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Benkirane-Jessel, Nadia [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Tenenbaum, Henri [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Siepmann, Juergen [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Siepmann, Florence [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Huck, Olivier [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]

Titre de la revue :

International Journal of Pharmaceutics

Nom court de la revue :

Int J Pharm

Numéro :

569

Pagination :

118564

Date de publication :

2019-07-25

ISSN :

1873-3476

Mot(s)-clé(s) :

Periodontitis
Inflammation
Porphyromonas gingivalis
Lipopolysaccharide
Infection

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Control of infection and inflammation is crucial for the success of periodontal treatment. In this study, in-situ forming implants (ISFI) loaded with chlorhexidine dihydrochloride (CHX) and ibuprofen (IBU) were developed ...
Lire la suite >Control of infection and inflammation is crucial for the success of periodontal treatment. In this study, in-situ forming implants (ISFI) loaded with chlorhexidine dihydrochloride (CHX) and ibuprofen (IBU) were developed and tested to optimize periodontal treatment outcomes. Release profiles were promising. Exposure to 1.5% and 5.3% CHX-IBU loaded ISFI's release media decreased significantly the P. gingivalis growth up to 20-fold and 35-fold, respectively, after 48 h (p < 0.05). The metabolic activity assay of gingival epithelial cells (EC) demonstrated 1.5% CHX-IBU-loaded ISFI to be non-toxic, therefore, it was selected for further experimentation. Furthermore, significant down-regulation of TNF-α release (34% at 6 h and 43% at 24 h, p < 0.05) in P. gingivalis lipopolysaccharide (Pg-LPS) stimulated EC exposed to 1.5% CHX-IBU ISFI release medium was demonstrated by ELISA. In vivo, 1.5% CHX-IBU ISFI was injected into the periodontal pocket in an experimental periodontitis mouse model and the reduction in inflammation and improvement in periodontal wound healing was evaluated through inflammatory cell scoring and histomorphometry at 7- and 15-days post-treatment. The results indicate that CHX-IBU loaded ISFI could be efficient as adjuvant to periodontal therapy for the control of infection and inflammation. Moreover, other (e.g., pro-regenerative) drugs could be incorporated into ISFI to further improve periodontal treatment outcomes.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Advanced Drug Delivery Systems (ADDS) - U1008

Date de dépôt :

2021-01-20T15:59:17Z
2024-02-23T11:42:34Z